Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI

NCT05014516 | Terminated

• 1 other identifier: 1000074027
• Study Type: observational
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

In this study the Investigators aim to deploy UTE and HP 129Xe MRI for structural and functional evaluation of persistent lung abnormalities in COVID-19 survivors.

Conditions

COVID-19 Respiratory Infection

Keywords

Lung MRI; 129Xenon

Outcome Measures

Primary Outcomes (1)

• Primary

  Determine if 129Xenon MRI can detect abnormalities in COVID19 survivors 3 months, 6 months, 1 year and 2 years post infection.

  4 years

Secondary Outcomes (6)

• Secondary 2A (i)

  3.5 years

• Secondary 2A (ii)

  3.5 years

• Secondary 2A (iii)

  3.5 years

• Secondary 2B

  3.5years

• Secondary 2C

  3.5 years

Study Arms (1)

Single arm

Those participants who have experienced a documented case (documented by positive COVID19 test and/or clinical history) mild or severe COVID19 infection including those with symptoms and those who were hospitalized with COVID19 infection, all of whom are within 3 months post recovery

Drug: 129Xenon gas

Interventions

129Xenon gas DRUG

Observational

Also known as: Hyperpolarized tracer gas

Single arm

Eligibility Criteria

• Age: 12 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

40 participants age ≥ 12 and ≤70 years who experienced a documented case (documented by positive COVID19 test and/or clinical history) mild or severe COVID19 infection including those with symptoms and those who were hospitalized with COVID19 infection, all of whom are within 3 months post recovery.

You may qualify if:

• Consent provided
• Aged 12-70 years old
• Meets MRI screening criteria
• Diagnosed with COVID19, documented by positive COVID19 test (Nasopharyngeal swab or saliva swab) and are within 3 months post recovery\*.
• Recovery from COVID19 is defined as asymptomatic for at least 2 weeks prior to study visit 1 and screen negative based on SickKids guidelines.

You may not qualify if:

• Pregnant or lactating\*
• A cold or flu within the last 2 weeks

Sponsors & Collaborators

• The Hospital for Sick Children: lead
• Western University: collaborator

Study Sites (1)

The Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada

Location

Related Publications (3)

• Kooner HK, Wyszkiewicz PV, Matheson AM, McIntosh MJ, Abdelrazek M, Dhaliwal I, Nicholson JM, Kirby M, Svenningsen S, Parraga G. Chest CT Airway and Vascular Measurements in Females with COPD or Long-COVID. COPD. 2024 Dec;21(1):2394129. doi: 10.1080/15412555.2024.2394129. Epub 2024 Sep 2.

  PMID: 39221567 DERIVED

• Kooner HK, McIntosh MJ, Matheson AM, Abdelrazek M, Albert MS, Dhaliwal I, Kirby M, Ouriadov A, Santyr GE, Venegas C, Radadia N, Svenningsen S, Nicholson JM, Parraga G. Postacute COVID-19 Syndrome: 129Xe MRI Ventilation Defects and Respiratory Outcomes 1 Year Later. Radiology. 2023 Apr;307(2):e222557. doi: 10.1148/radiol.222557. Epub 2023 Feb 7.

  PMID: 36749209 DERIVED

• Kooner HK, McIntosh MJ, Matheson AM, Venegas C, Radadia N, Ho T, Haider EA, Konyer NB, Santyr GE, Albert MS, Ouriadov A, Abdelrazek M, Kirby M, Dhaliwal I, Nicholson JM, Nair P, Svenningsen S, Parraga G. 129Xe MRI ventilation defects in ever-hospitalised and never-hospitalised people with post-acute COVID-19 syndrome. BMJ Open Respir Res. 2022 May;9(1):e001235. doi: 10.1136/bmjresp-2022-001235.

  PMID: 35584850 DERIVED

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Senior Scientist

Study Record Dates

• First Submitted: July 30, 2021
• First Posted: August 20, 2021
• Study Start: August 5, 2021
• Primary Completion: March 20, 2024
• Study Completion: March 20, 2024
• Last Updated: August 1, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)